$SSY
SUNLINK HEALTH SYSTEMS INC

2017 Q2 Form 10-K Financial Statement

#000119312518282598 Filed on September 25, 2018

View on sec.gov

Income Statement

Concept 2017 Q2 2017
Revenue $12.29M $53.29M
YoY Change -12.6% -15.99%
Cost Of Revenue $4.330M $19.92M
YoY Change -10.17% 513.21%
Gross Profit $7.960M $33.37M
YoY Change -475.47% -44.55%
Gross Profit Margin 64.78% 62.62%
Selling, General & Admin $7.280M $28.99M
YoY Change -25.25%
% of Gross Profit 91.46% 86.87%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $540.0K $1.987M
YoY Change -77.87% -18.43%
% of Gross Profit 6.78% 5.95%
Operating Expenses $9.340M $57.36M
YoY Change -722.67% 17.8%
Operating Profit -$1.380M -$4.510M
YoY Change 122.58% -30.86%
Interest Expense -$130.0K $635.0K
YoY Change -38.1% -24.67%
% of Operating Profit
Other Income/Expense, Net $1.540M
YoY Change -196.25%
Pretax Income -$3.040M -$2.471M
YoY Change 79.88% -66.41%
Income Tax -$280.0K -$512.0K
% Of Pretax Income
Net Earnings -$2.408M $2.688M
YoY Change 95.14% -119.09%
Net Earnings / Revenue -19.6% 5.04%
Basic Earnings Per Share -$0.26 $0.29
Diluted Earnings Per Share -$0.26 $0.29
COMMON SHARES
Basic Shares Outstanding 9.163M shares 9.346M shares
Diluted Shares Outstanding 9.163M shares 9.346M shares

Balance Sheet

Concept 2017 Q2 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.50M $10.49M
YoY Change 218.18% 221.8%
Cash & Equivalents $10.49M $10.49M
Short-Term Investments
Other Short-Term Assets $4.100M $4.062M
YoY Change -30.51% -30.6%
Inventory $2.159M $2.159M
Prepaid Expenses
Receivables $5.900M $5.906M
Other Receivables $0.00 $0.00
Total Short-Term Assets $22.62M $22.62M
YoY Change 26.43% 26.43%
LONG-TERM ASSETS
Property, Plant & Equipment $10.29M $10.29M
YoY Change -20.81% -20.81%
Goodwill $0.00
YoY Change -100.0%
Intangibles $1.587M
YoY Change -41.11%
Long-Term Investments
YoY Change
Other Assets $838.0K $838.0K
YoY Change 14.48% -91.67%
Total Long-Term Assets $12.72M $12.72M
YoY Change -51.49% -51.49%
TOTAL ASSETS
Total Short-Term Assets $22.62M $22.62M
Total Long-Term Assets $12.72M $12.72M
Total Assets $35.34M $35.34M
YoY Change -19.88% -19.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.571M $1.571M
YoY Change -53.67% -53.67%
Accrued Expenses $658.0K $3.375M
YoY Change -65.06% -25.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $6.710M $6.710M
YoY Change -10.21% -10.21%
Total Short-Term Liabilities $12.31M $12.31M
YoY Change -38.59% -38.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $289.0K $1.329M
YoY Change -32.0% -16.2%
Total Long-Term Liabilities $1.329M $1.329M
YoY Change -70.89% -70.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.31M $12.31M
Total Long-Term Liabilities $1.329M $1.329M
Total Liabilities $13.64M $13.64M
YoY Change -44.58% -44.58%
SHAREHOLDERS EQUITY
Retained Earnings $4.336M
YoY Change 163.11%
Common Stock $17.68M
YoY Change -3.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.70M $21.69M
YoY Change
Total Liabilities & Shareholders Equity $35.34M $35.34M
YoY Change -19.88% -19.88%

Cashflow Statement

Concept 2017 Q2 2017
OPERATING ACTIVITIES
Net Income -$2.408M $2.688M
YoY Change 95.14% -119.09%
Depreciation, Depletion And Amortization $540.0K $1.987M
YoY Change -77.87% -18.43%
Cash From Operating Activities -$610.0K -$5.610M
YoY Change 335.71% 1216.9%
INVESTING ACTIVITIES
Capital Expenditures -$530.0K $1.630M
YoY Change 103.85% 21.01%
Acquisitions
YoY Change
Other Investing Activities $540.0K $20.10M
YoY Change 2600.0% 95609.52%
Cash From Investing Activities $0.00 $18.47M
YoY Change -100.0% -1391.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $641.0K
YoY Change
Debt Paid & Issued, Net $3.985M
YoY Change 364.99%
Cash From Financing Activities -140.0K -5.626M
YoY Change -46.15% 556.48%
NET CHANGE
Cash From Operating Activities -610.0K -5.610M
Cash From Investing Activities 0.000 18.47M
Cash From Financing Activities -140.0K -5.626M
Net Change In Cash -750.0K 7.233M
YoY Change 17.19% -366.61%
FREE CASH FLOW
Cash From Operating Activities -$610.0K -$5.610M
Capital Expenditures -$530.0K $1.630M
Free Cash Flow -$80.00K -$7.240M
YoY Change -166.67% 308.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7346814 shares
CY2017Q4 dei Entity Public Float
EntityPublicFloat
5121452
CY2016Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
991000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax
AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
-420000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-420000
CY2016Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3261000
CY2016Q2 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
826000
CY2016Q2 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
1583000
CY2016Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19489000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
635642 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.07
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
22621000
CY2017Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
552000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18319000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
13103000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1571000
CY2017Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6458000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax
AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
-327000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-327000
CY2017Q2 us-gaap Assets
Assets
35336000
CY2017Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
12107000
CY2017Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
12000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10494000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10494000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9163000 shares
CY2017Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9163000 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
4581000
CY2017Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11120000
CY2017Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7751000
CY2017Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2218000
CY2017Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11120000
CY2017Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
59000
CY2017Q2 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
891000
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions
231000
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
153000
CY2017Q2 us-gaap Defined Benefit Plan Amounts Recognized In Balance Sheet
DefinedBenefitPlanAmountsRecognizedInBalanceSheet
-615000
CY2017Q2 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
1506000
CY2017Q2 us-gaap Defined Benefit Plan Funded Status Of Plan
DefinedBenefitPlanFundedStatusOfPlan
-615000
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2098000
CY2017Q2 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0
CY2017Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1587000
CY2017Q2 us-gaap Inventory Net
InventoryNet
2159000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12314000
CY2017Q2 us-gaap Land
Land
902000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35336000
CY2017Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1329000
CY2017Q2 us-gaap Long Term Debt
LongTermDebt
7203000
CY2017Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
6710000
CY2017Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2017Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
15600000
CY2017Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
2425000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
838000
CY2017Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1277000
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
289000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10290000
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2017Q2 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3062000
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28609000
CY2017Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
5906000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4336000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2017Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
21693000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
620142 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.81
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
680142 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.80
CY2017Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
493000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q2 ssy Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax
DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax
525000
CY2017Q2 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
1040000
CY2017Q2 ssy Prepaid Accrued Benefit Cost
PrepaidAccruedBenefitCost
-90000
CY2017Q2 ssy Defined Benefit Plan Amounts Recognized In Prepaid Benefit Cost
DefinedBenefitPlanAmountsRecognizedInPrepaidBenefitCost
-90000
CY2017Q2 ssy Deferred Tax Assets Depreciation Expense
DeferredTaxAssetsDepreciationExpense
-255000
CY2017Q2 ssy Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
963000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
290000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
13110000
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
529000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19589000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10947000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1239000
CY2018Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5352000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax
AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
-177000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-177000
CY2018Q2 us-gaap Assets
Assets
26176000
CY2018Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
12895000
CY2018Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
0
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3456000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3456000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7347000 shares
CY2018Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7347000 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
3673000
CY2018Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8373000
CY2018Q2 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Four
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
58000
CY2018Q2 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Two
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
61000
CY2018Q2 us-gaap Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year
DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
100000
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6367000
CY2018Q2 us-gaap Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months
DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
98000
CY2018Q2 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Five
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
69000
CY2018Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1185000
CY2018Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8373000
CY2018Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
58000
CY2018Q2 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Three
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
61000
CY2018Q2 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
895000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions
132000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
111000
CY2018Q2 us-gaap Defined Benefit Plan Amounts Recognized In Balance Sheet
DefinedBenefitPlanAmountsRecognizedInBalanceSheet
-525000
CY2018Q2 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
1420000
CY2018Q2 us-gaap Defined Benefit Plan Funded Status Of Plan
DefinedBenefitPlanFundedStatusOfPlan
-525000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1959000
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
117000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
26000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
21000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
26000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
100000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
290000
CY2018Q2 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
305000
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1470000
CY2018Q2 us-gaap Inventory Net
InventoryNet
1894000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4851000
CY2018Q2 us-gaap Land
Land
902000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26176000
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4139000
CY2018Q2 us-gaap Long Term Debt
LongTermDebt
3277000
CY2018Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
3277000
CY2018Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
255000
CY2018Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
333000
CY2018Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
313000
CY2018Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
294000
CY2018Q2 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
1729000
CY2018Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
254000
CY2018Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
354000
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2803000
CY2018Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
16198000
CY2018Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
2660000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
267000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1340000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
427000
CY2018Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
14600000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
885000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
550000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
95000
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1108000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
340000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10406000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2018Q2 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2937000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29995000
CY2018Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
4823000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2743000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17186000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.52
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
636000 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.52
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
651000 shares
CY2018Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
219000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018Q2 ssy Long Term Debt Contractual Commitments For Interest In Year Four
LongTermDebtContractualCommitmentsForInterestInYearFour
138000
CY2018Q2 ssy Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax
DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax
376000
CY2018Q2 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
996000
CY2018Q2 ssy Long Term Debt Contractual Commitments For Interest In Year Two
LongTermDebtContractualCommitmentsForInterestInYearTwo
176000
CY2018Q2 ssy Prepaid Accrued Benefit Cost
PrepaidAccruedBenefitCost
-149000
CY2018Q2 ssy Long Term Debt Contractual Commitments For Interest In Year Five
LongTermDebtContractualCommitmentsForInterestInYearFive
117000
CY2018Q2 ssy Defined Benefit Plan Amounts Recognized In Prepaid Benefit Cost
DefinedBenefitPlanAmountsRecognizedInPrepaidBenefitCost
-149000
CY2018Q2 ssy Long Term Debt Contractual Commitments
LongTermDebtContractualCommitments
999000
CY2018Q2 ssy Long Term Debt Contractual Commitments For Interest In Next Twelve Months
LongTermDebtContractualCommitmentsForInterestInNextTwelveMonths
177000
CY2018Q2 ssy Long Term Debt Contractual Commitments For Interest In Year After Five Year
LongTermDebtContractualCommitmentsForInterestInYearAfterFiveYear
233000
CY2018Q2 ssy Long Term Debt Contractual Commitments For Interest In Year Three
LongTermDebtContractualCommitmentsForInterestInYearThree
158000
CY2018Q2 ssy Plan Expected To Pay In Pension Benefits Through Three Years
PlanExpectedToPayInPensionBenefitsThroughThreeYears
455000
CY2018Q2 ssy Deferred Tax Assets Depreciation Expense
DeferredTaxAssetsDepreciationExpense
-97000
CY2018Q2 ssy Plans Assets Invested In Equity Investments
PlansAssetsInvestedInEquityInvestments
0.32 pure
CY2018Q2 ssy Plans Assets Invested In Cash And Short Term Investments
PlansAssetsInvestedInCashAndShortTermInvestments
0.53 pure
CY2018Q2 ssy Plans Assets Invested In Fixed Income Investments
PlansAssetsInvestedInFixedIncomeInvestments
0.15 pure
CY2018Q2 ssy Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
617000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1355000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36000 shares
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
64000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
142000
CY2017 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-131000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7233000
CY2017 us-gaap Charity Care Reimbursements Received
CharityCareReimbursementsReceived
0
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2781000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
54000
CY2017 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-566000
CY2017 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
0.0350 pure
CY2017 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
54000
CY2017 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
3000
CY2017 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
0.0000 pure
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
140000
CY2017 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
-53000
CY2017 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
0.0400 pure
CY2017 us-gaap Defined Benefit Plan Plan Assets Benefits Paid
DefinedBenefitPlanPlanAssetsBenefitsPaid
78000
CY2017 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
78000
CY2017 us-gaap Depreciation
Depreciation
1845000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1987000
CY2017 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
4647000
CY2017 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
14621000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5478000
CY2017 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-1000000
CY2017 us-gaap Profit Loss
ProfitLoss
2688000
CY2017 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.21
CY2017 us-gaap Income Tax Reconciliation Tax Settlements State And Local
IncomeTaxReconciliationTaxSettlementsStateAndLocal
-154000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1914000
CY2017 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
7265000
CY2017 us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
2829000
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2017 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2917000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2916000
CY2017 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-243000
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1427000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2471000
CY2017 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.50
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-512000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155000
CY2017 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-260000
CY2017 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1959000
CY2017 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.21
CY2017 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
4647000
CY2017 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.50
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
134000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-840000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
468000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3119000
CY2017 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
478000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
16000
CY2017 us-gaap Interest Expense
InterestExpense
635000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-453000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
570000
CY2017 us-gaap Labor And Related Expense
LaborAndRelatedExpense
23378000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18469000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5626000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5610000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
2688000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
93000
CY2017 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
93000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-4510000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
561000
CY2017 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
5616000
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
641000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1630000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.55
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.21
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
72000 shares
CY2017 us-gaap Supplies Expense
SuppliesExpense
1844000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
438000
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3985000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53288000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
64000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0130 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
27500 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.21
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.87 pure
CY2017 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
641000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9346000 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9346000 shares
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017 ssy Increase Decrease Changes In Deferred Income Taxes
IncreaseDecreaseChangesInDeferredIncomeTaxes
2321000
CY2017 ssy Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
53766000
CY2017 ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
1630000
CY2017 ssy Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
193000
CY2017 ssy Defined Contribution Plan Employer Matching Contribution
DefinedContributionPlanEmployerMatchingContribution
152000
CY2017 ssy Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax
OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax
93000
CY2017 ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
64000
CY2017 ssy Other Comprehensive Income Minimum Pension Liabilities Net Adjustment Tax
OtherComprehensiveIncomeMinimumPensionLiabilitiesNetAdjustmentTax
58000
CY2017 ssy Increase Decrease In Third Party Payor Settlements
IncreaseDecreaseInThirdPartyPayorSettlements
1224000
CY2017 ssy Unrecognized Actuarial Loss
UnrecognizedActuarialLoss
525000
CY2017 ssy Share Based Payment Award Options Forfeited In Period Range Of Exercise Price
ShareBasedPaymentAwardOptionsForfeitedInPeriodRangeOfExercisePrice
6.55
CY2017 ssy Share Based Compensation Arrangement By Share Based Payments Award Options Grants In Period Range Of Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodRangeOfExercisePrice
1.21
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8000
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1235000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
61000 shares
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
117000
CY2018 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-311000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7038000
CY2018 us-gaap Charity Care Reimbursements Received
CharityCareReimbursementsReceived
7000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <b><i>Concentrations of Credit Risk</i></b>&#x2014;SunLink&#x2019;s Healthcare Services segment subsidiaries grant unsecured credit to their patients, most of who reside in the service area of the subsidiaries&#x2019; facilities and are insured under third-party agreements. Medicare and Medicaid patient accounts represent SunLink&#x2019;s only significant concentrations of credit risk. For SunLink&#x2019;s Healthcare Services segment, Medicare net revenues were approximately 43% and 40% of net revenues for the years ended June&#xA0;30, 2018 and 2017, respectively. For SunLink&#x2019;s Healthcare Services segment, Medicaid was approximately 40% and 43% net revenues for the years ended June&#xA0;30, 2018 and 2017, respectively. For SunLink&#x2019;s Healthcare Services segment, Medicare receivables were approximately 45% and 53% of receivables&#x2014;net at June&#xA0;30, 2018 and 2017, respectively, while Medicaid receivables were approximately 36% and 24% of receivables&#x2014;net at June&#xA0;30, 2018 and 2017, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> SunLink&#x2019;s Pharmacy segment subsidiary grants unsecured credit to individual customers and institutional customers.&#xA0;Individual customers primarily are insured under third-party agreements, including Medicare and Medicaid, while the institutional customers are granted credit according to their determined credit risk.&#xA0;Medicare receivables were approximately 19% and 19% of the Pharmacy&#x2019;s receivables at June&#xA0;30, 2018 and 2017, respectively, while Medicaid receivables were approximately 18% and 19% of the segments receivable at June&#xA0;30, 2018 and 2017, respectively. Approximately 63% and 62% of the Pharmacy&#x2019;s net receivables at June&#xA0;30, 2018 and 2017, respectively, were private insurance and institutional customers&#x2019; receivables. Net revenues for the Pharmacy segment for the fiscal year ended June&#xA0;30, 2018 and 2017 were approximately 35% and 35% Medicare, respectively, and approximately 26% and 23% Medicaid, respectively.</p> </div>
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1443000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2018 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-345000
CY2018 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
0.0380 pure
CY2018 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
55000
CY2018 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
-2000
CY2018 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
0.0000 pure
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
100000
CY2018 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
-47000
CY2018 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
0.0400 pure
CY2018 us-gaap Defined Benefit Plan Plan Assets Benefits Paid
DefinedBenefitPlanPlanAssetsBenefitsPaid
94000
CY2018 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
94000
CY2018 us-gaap Depreciation
Depreciation
1741000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1858000
CY2018 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-460000
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Type
DocumentType
10-K
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1858000
CY2018 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
-113000
CY2018 us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
0
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0000096793
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Registrant Name
EntityRegistrantName
SUNLINK HEALTH SYSTEMS INC
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
169000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
169000
CY2018 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
944000
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-238000
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1478000
CY2018 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.14
CY2018 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.06
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-345000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2971000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12000
CY2018 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1083000
CY2018 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1133000
CY2018 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.14
CY2018 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-460000
CY2018 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.06
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-407000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2889000
CY2018 us-gaap Income Tax Reconciliation Tax Settlements State And Local
IncomeTaxReconciliationTaxSettlementsStateAndLocal
1000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-391000
CY2018 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
509000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-21000
CY2018 us-gaap Interest Expense
InterestExpense
359000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-154000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
319000
CY2018 us-gaap Labor And Related Expense
LaborAndRelatedExpense
23551000
CY2018 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>13. ECONOMIC DAMAGES</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys&#x2019; fees) were received. The net settlements are recognized as a gain in the results for the year ended June&#xA0;30, 2018.</p> </div>
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>1. BUSINESS OPERATIONS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> SunLink Health Systems, Inc., through subsidiaries (&#x201C;SunLink&#x201D;, &#x201C;we&#x201D;, &#x201C;our&#x201D;, &#x201C;ours&#x201D;, &#x201C;us&#x201D; or the &#x201C;Company&#x201D;), owns businesses which are providers of healthcare services in certain markets in the United States. SunLink&#x2019;s business is composed of the ownership of two business segments:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">The Healthcare Services segment, which is composed of:</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">A subsidiary which owns and operates&#xA0;an <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">84-licensed-bed,</font></font> acute care hospital, which includes an <font style="WHITE-SPACE: nowrap">18-bed</font> geriatric psychology unit, and a <font style="WHITE-SPACE: nowrap">66-bed</font> nursing home.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">A subsidiary which owns and operates a <font style="WHITE-SPACE: nowrap">100-bed</font> nursing home.&#xA0;This subsidiary also owns a hospital facility and leases the emergency department to an outside third party.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Three subsidiaries which own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">A subsidiary which provides information technology (IT) to outside customers and to SunLink subsidiaries</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The Pharmacy segment, which is composed of four operational areas:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Retail pharmacy products and services, all of which are conducted in rural markets;</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Institutional pharmacy services;</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> <font style="WHITE-SPACE: nowrap">Non-institutional</font> Pharmacy Services and</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Durable medical equipment.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> SunLink subsidiaries have conducted the Healthcare Services business since 2001 and the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael&#x2019;s Cashway Pharmacy,&#xA0;Inc. (&#x201C;Carmichael&#x201D;), a subsidiary of our SunLink ScriptsRx, LLC subsidiary, and is composed of a pharmacy business acquired in April 2008 with four service lines.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as &#x201C;SunLink&#x201D;, &#x201C;we&#x201D;, &#x201C;our&#x201D;, &#x201C;ours&#x201D;, &#x201C;us&#x201D; or the &#x201C;Company.&#x201D; This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any asset, business or property.&#xA0;The Trace, pharmacy operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc.</p> </div>
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1436000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5998000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
396000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-1593000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
150000
CY2018 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
150000
CY2018 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-1994000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
626000
CY2018 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
5125000
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3072000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1861000
CY2018 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
425000
CY2018 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
1000000
CY2018 us-gaap Property Plant And Equipment Depreciation Methods
PropertyPlantAndEquipmentDepreciationMethods
Depreciation is recognized over the estimated useful lives of the assets, which range from 3 to 45 years, on a straight-line basis.
CY2018 us-gaap Profit Loss
ProfitLoss
-1593000
CY2018 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Estimated useful lives of the assets, which range from 3 to 45 years, on a straight-line basis.
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
703000
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3926000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52872000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
8000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M26D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29142 shares
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018 us-gaap Supplies Expense
SuppliesExpense
1774000
CY2018 dei Trading Symbol
TradingSymbol
SSY
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.00
CY2018 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
3072000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8283000 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8283000 shares
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <b><i>Management Estimates</i></b>&#x2014;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates made by management involve reserves for adjustments to net patient service revenues, evaluation of the recoverability of assets, including accounts receivable and intangible assets, and the assessment of litigation and contingencies, including income taxes and related tax asset valuation allowances, all as discussed in more detail in the remainder of these notes to the consolidated financial statements. Actual results could differ materially from these estimates.</p> </div>
CY2018 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2018 ssy Increase Decrease Changes In Deferred Income Taxes
IncreaseDecreaseChangesInDeferredIncomeTaxes
0
CY2018 ssy Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
53381000
CY2018 ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
1861000
CY2018 ssy Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
112000
CY2018 ssy Defined Contribution Plan Employer Matching Contribution
DefinedContributionPlanEmployerMatchingContribution
157000
CY2018 ssy Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax
OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax
150000
CY2018 ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
21000
CY2018 ssy Other Comprehensive Income Minimum Pension Liabilities Net Adjustment Tax
OtherComprehensiveIncomeMinimumPensionLiabilitiesNetAdjustmentTax
103000
CY2018 ssy Increase Decrease In Third Party Payor Settlements
IncreaseDecreaseInThirdPartyPayorSettlements
368000
CY2018 ssy Unrecognized Actuarial Loss
UnrecognizedActuarialLoss
376000
CY2018 ssy Net Operating Loss Carry Forwards Expire Period
NetOperatingLossCarryForwardsExpirePeriod
2023 through 2043
CY2018 ssy Age Of Participants To Take Monthly Pension Benefits One
AgeOfParticipantsToTakeMonthlyPensionBenefitsOne
P65Y
CY2018 ssy Maximum Period Of Accounts Receivable Written Off
MaximumPeriodOfAccountsReceivableWrittenOff
P120D
CY2018 ssy Share Based Payment Award Options Forfeited In Period Range Of Exercise Price
ShareBasedPaymentAwardOptionsForfeitedInPeriodRangeOfExercisePrice
8.00
CY2018 ssy Expected Return On Investment
ExpectedReturnOnInvestment
0.04 pure
ssy Number Of Hospitals Sold
NumberOfHospitalsSold
3 Hospital

Files In Submission

Name View Source Status
0001193125-18-282598-index-headers.html Edgar Link pending
0001193125-18-282598-index.html Edgar Link pending
0001193125-18-282598.txt Edgar Link pending
0001193125-18-282598-xbrl.zip Edgar Link pending
d622610d10k.htm Edgar Link pending
d622610dex211.htm Edgar Link pending
d622610dex231.htm Edgar Link pending
d622610dex311.htm Edgar Link pending
d622610dex312.htm Edgar Link pending
d622610dex321.htm Edgar Link pending
d622610dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ssy-20180630.xml Edgar Link completed
ssy-20180630.xsd Edgar Link pending
ssy-20180630_cal.xml Edgar Link unprocessable
ssy-20180630_def.xml Edgar Link unprocessable
ssy-20180630_lab.xml Edgar Link unprocessable
ssy-20180630_pre.xml Edgar Link unprocessable